185122-75-2

Usage

Uses

Used in Pharmaceutical Applications:
5H-Cyclopenta[b]pyridin-7-amine, 6,7-dihydrois used as a potential pharmaceutical agent for its diverse biological activities, including antifungal, antiviral, and anticancer properties. Its heterocyclic amine structure contributes to its therapeutic potential in various medical applications.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, 5H-Cyclopenta[b]pyridin-7-amine, 6,7-dihydroserves as a building block for the synthesis of more complex chemical compounds. Its unique structure and reduced state may offer new avenues for the development of novel therapeutic agents and contribute to the advancement of drug discovery.
Used in Drug Synthesis:
5H-Cyclopenta[b]pyridin-7-amine, 6,7-dihydrois used as a key intermediate in the synthesis of various pharmaceutical compounds. Its heterocyclic nature and functional groups provide opportunities for further chemical modifications, enabling the creation of new drugs with improved efficacy and selectivity.
Used in Drug Discovery:
As a chemical compound with potential pharmaceutical applications, 5H-Cyclopenta[b]pyridin-7-amine, 6,7-dihydrois utilized in drug discovery processes. Its diverse biological activities and unique structural features make it a promising candidate for the development of new therapeutic agents targeting various diseases and conditions.
Used in Chemical Research:
5H-Cyclopenta[b]pyridin-7-amine, 6,7-dihydrois employed in chemical research to explore its reactivity, stability, and potential interactions with other molecules. Understanding its properties and behavior can contribute to the advancement of chemical knowledge and the development of new synthetic methods and applications.

InChI:InChI=1/C8H10N2/c9-7-4-3-6-2-1-5-10-8(6)7/h1-2,5,7H,3-4,9H2

Upstream product

• 1071727-78-0 5,6-dihydro-[1]pyrindin-7-one O-methyl-oxime 

Downstream Products

• 1228571-16-1 (S)-5H,6H,7H-cyclopenta[b]pyridin-7-amine 
• 1228571-16-1 (R)-6,7-dihydro-5H-cyclopenta[b]pyridin-7-amine 
• 298181-96-1 C₂₈H₂₇N₅O₄S 

Relevant academic research and scientific papers

Discovery of novel small molecule orally bioavailable C-X-C chemokine receptor 4 antagonists that are potent inhibitors of T-tropic (X4) HIV-1 replication

The redesign of azamacrocyclic CXCR4 chemokine receptor antagonists resulted in the discovery of novel, small molecule, orally bioavailable compounds that retained T-tropic (CXCR4 using, X4) anti-HIV-1 activity. A structure-activity relationship (SAR) was determined on the basis of the inhibition of replication of X4 HIV-1 NL4.3 in MT-4 cells. As a result of lead optimization, we identified (S)-N′-((1H-benzo[d]imidazol-2-yl)methyl)- N′-(5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine (AMD070) 2 as a potent and selective antagonist of CXCR4 with an IC50 value of 13 nM in a CXCR4 125I-SDF inhibition binding assay. Compound 2 inhibited the replication of T-tropic HIV-1 (NL4.3 strain) in MT-4 cells and PBMCs with an IC50 of 2 and 26 nM, respectively, while remaining noncytotoxic to cells at concentrations exceeding 23 μM. The pharmacokinetics of 2 was evaluated in rat and dog, and good oral bioavailability was observed in both species. This compound represents the first small molecule orally bioavailable CXCR4 antagonist that was developed for the treatment of HIV-1 infection.

Identification of (R)-1-(5-tert-butyl-2,3-dihydro-1H-inden-1-yl)-3-(1H- indazol-4-yl)urea (ABT-102) as a potent TRPV1 antagonist for pain management

Vanilloid receptor TRPV1 is a cation channel that can be activated by a wide range of noxious stimuli, including capsaicin, acid, and heat. Blockade of TRPV1 activation by selective antagonists is under investigation by several pharmaceutical companies in an effort to identify novel agents for pain management. Here we report that replacement of substituted benzyl groups by an indan rigid moiety in a previously described N-indazole-N′-benzyl urea series led to a number of TRPV1 antagonists with significantly increased in vitro potency and enhanced drug-like properties. Extensive evaluation of pharmacological, pharmacokinetic, and toxicological properties of synthesized analogs resulted in identification of (R)-7 (ABT-102). Both the analgesic activity and drug-like properties of (R)-7 support its advancement into clinical pain trials.

SUBSTITUTED FLUOROETHYL UREAS AS ALPHA 2 ADRENERGIC AGENTS

Therapeutic compounds, and methods, compositions, and medicaments related thereto are disclosed herein.

Chemokine receptor binding heterocyclic compounds

This invention relates to a novel class of heterocyclic compounds that bind chemokine receptors, inhibiting the binding of their natural ligands thereby. These compounds result in protective effects against infection by HIV through binding to chemokine receptors, including CXCR4 and CCR5, thus inhibiting the subsequent binding by these chemokines. The present invention provides a compound of Formula I wherein, W is a nitrogen atom and Y is absent or, W is a carbon atom and Y═H; R1to R7may be the same or different and are independently selected from hydrogen or straight, branched or cyclic C1-6alkyl; R8is a substituted heterocyclic group or a substituted aromatic group Ar is an aromatic or heteroaromatic ring each optionally substituted at single or multiple, non-linking positions with electron-donating or withdrawing groups; n and n′ are independently, 0-2; X is a group of the formula: Wherein, Ring A is an optionally substituted, saturated or unsaturated 5 or 6-membered ring, and P is an optionally substituted carbon atom, an optionally substituted nitrogen atom, sulfur or oxygen atom. Ring B is an optionally substituted 5 to 7-membered ring. Ring A and Ring B in the above formula can be connected to the group W from any position via the group V, wherein V is a chemical bond, a (CH2)n″group (where n″=0-2) or a C═O group. Z is, (1) a hydrogen atom, (2) an optionally substituted C1-6alkyl group, (3) a C0-6alkyl group substituted with an optionally substituted aromatic or heterocyclic group, (4) an optionally substituted C0-6alkylamino or C3-7cycloalkylamino group, (5) an optionally substituted carbonyl group or sulfonyl. These compounds further include any pharmaceutically acceptable acid addition salts and metal complexes thereof and any stereoisomeric forms and mixtures of stereoisomeric forms thereof.

Substituted aryl 1,4-pyrazine derivatives

Substituted aryl 1,4-pyrazine derivatives and their use in treating anxiety disorders, depression and stress related disorders are disclosed.